Jodie Wehling
Vice President, Market Access & Head of Market Access, Trade & Distribution Mesoblast Ltd.
Jodie Wehling is Vice President and Head of Market Access, Trade & Distribution, and Contracting at Mesoblast. She is a global and U.S. market access executive focused on optimizing patient access to innovative therapies, including cell and gene therapies, oncology, rare disease, immunology, multiple sclerosis, and cardiovascular treatments. Jodie is recognized for launch excellence and strategic leadership, having supported the launch of nine therapies in the past seven years. She builds and leads high-performing teams across market access, managed markets, marketing, and sales while developing value-driven strategies spanning pricing, payer engagement, patient services, policy, and distribution to ensure sustainable access to transformative therapies.
Seminars
- Navigating transplant center access barriers unique to allogeneic cell therapies including cost committees’ quality reviews and operational assumptions to accelerate adoption
- Educating payers and Medicaid programs on acute treatment timelines for allogeneic therapies where patients need access in days not weeks
- Expanding delivery beyond major academic centers by enabling smaller transplant programs to confidently administer allogeneic cell therapies through new access education and distribution approaches
- Addressing access obstacles and new considerations in emerging indications to expand CAR‑T cell therapy and gene therapy delivery beyond oncology and smaller indications
- Policy challenges and opportunities to broaden treatment reach across the US outside major academic centres and improving patient access pathways
- Identifying key areas of reimbursement and access policy shaping that will enable future patients to receive innovative therapies
